资源类型

期刊论文 2

年份

2021 1

2014 1

关键词

FLT3抑制剂 1

吉瑞替尼 1

奎扎替尼 1

急性髓系白血病 1

米哚妥林 1

索拉非尼 1

靶向治疗 1

展开 ︾

检索范围:

排序: 展示方式:

Advances in managing hepatocellular carcinoma

null

《医学前沿(英文)》 2014年 第8卷 第2期   页码 175-189 doi: 10.1007/s11684-014-0332-4

摘要:

Multiple modalities for treatment of hepatocellular carcinoma are available, depending on tumor size and number. Surgical resection remains the gold standard, so long as the residual liver function reserve is sufficient. In patients with advanced cirrhosis, liver transplantation is the preferred option, as these patients may not have adequate hepatic reserve after resection. Salvage liver transplantation has also become an option for a select few patients who recur after surgical resection. Ablative techniques have been used for palliation as well as to either completely destroy the tumor, act as an adjunct to resection, or downstage the tumor to meet Milan criteria such that a patient may be a candidate for liver transplantation. Radiofrequency ablation, microwave ablation, chemoembolization, radioembolization, and irreversible electroporation have all been used in this capacity. Currently, sorafenib is the only US Food and Drug Administration-approved chemotherapeutic for hepatocellular carcinoma. The efficacy of sorafenib, in combination with other agents, transarterial chemoembolization, and surgical resection is currently being investigated. Sunitinib and brivanib, tyrosine kinase inhibitors, have failed as potential first- or second-line options for chemotherapy. Bevacizumab in combination with erlotinib is also currently being studied. Final analysis for ramucirumab and axitinib are pending. Tivantinib, a selective mesenchymal-epithelial transition factor (MET) inhibitor, is also undergoing clinical trials for efficacy in MET-high tumors. This review serves to emphasize the current and new technologies emerging in the treatment of hepatocellular carcinoma.

关键词: hepatocellular carcinoma     radiofrequency ablation     microwave ablation     chemoembolization     radioembolization     sorafenib     irreversible electroporation    

抑制FLT3 ——急性髓系白血病分子靶向治疗的原型 Review

Meira Yisraeli Salman, Jacob M. Rowe, Nir Weigert

《工程(英文)》 2021年 第7卷 第10期   页码 1354-1368 doi: 10.1016/j.eng.2021.05.020

摘要:

急性髓系白血病(AML)的现代治疗始于1973年,首例柔红霉素和阿糖胞苷联合治疗法的成功随后拯救了大约45%的患者。准确的AML诊断依赖于形态学方法,其最初仅由细胞化学手段辅助。与急性淋巴细胞白血病(ALL)不同,至少在20世纪70年代和80年代,免疫分型在AML的诊断中几乎不起作用。可靠的细胞遗传学方法的出现为AML的预后发展带来了翻天覆地的变化。通过核型分析,可以对不同的AML实现分类与分层,以进行各种治疗。借助细胞上抗原标记物的免疫表型鉴定,独特的突变图谱可以里程碑式地进一步对 AML 患者进行分类。所有的这些进展都随着对肿瘤负荷[即微小残留病变(minimal residual disease, MRD)]的重要性的理解而成为AML患者管理的关键。MRD的疗效在过去10年迅速发展,其特异性从免疫分型的10-3发展到聚合酶链反应(PCR)的10-4(且仅对于部分AML患者有效),并最终在具有下一代测序(NGS)技术的灵敏度极高的细胞中发展至10-5甚至10-6。所有这些进步都促进了个性化医疗概念的发展,并带来了可以准确用于特定诊断亚型的靶向药物。可以精准预测与测量其响应。这些靶向药物现已成为AML管理的基础,其疗效显著提高,而毒性则显著下降。本文的重点是研究最为深入的AML靶向药物之一——FMS样酪氨酸激酶3(FLT3)抑制剂,它影响了AML的预后与治疗。作为已被批准的其他新兴靶向药物以及目前正在开发的靶向药物的原型,本文将选择性地对FLT3抑制剂展开详细讨论。

关键词: 急性髓系白血病     靶向治疗     FLT3抑制剂     米哚妥林     吉瑞替尼     奎扎替尼     索拉非尼    

标题 作者 时间 类型 操作

Advances in managing hepatocellular carcinoma

null

期刊论文

抑制FLT3 ——急性髓系白血病分子靶向治疗的原型

Meira Yisraeli Salman, Jacob M. Rowe, Nir Weigert

期刊论文